Veronica Bunn

1.4k total citations · 1 hit paper
26 papers, 422 citations indexed

About

Veronica Bunn is a scholar working on Pulmonary and Respiratory Medicine, Statistics and Probability and Oncology. According to data from OpenAlex, Veronica Bunn has authored 26 papers receiving a total of 422 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 11 papers in Statistics and Probability and 10 papers in Oncology. Recurrent topics in Veronica Bunn's work include Lung Cancer Treatments and Mutations (13 papers), Statistical Methods in Clinical Trials (9 papers) and Colorectal Cancer Treatments and Studies (6 papers). Veronica Bunn is often cited by papers focused on Lung Cancer Treatments and Mutations (13 papers), Statistical Methods in Clinical Trials (9 papers) and Colorectal Cancer Treatments and Studies (6 papers). Veronica Bunn collaborates with scholars based in United States, China and South Korea. Veronica Bunn's co-authors include Jianchang Lin, Shu Jin, Pasi A. Jänne, Suresh S. Ramalingam, James Chih‐Hsin Yang, Minal Mehta, Tarek Mekhail, Gregory J. Riely, Enriqueta Felip and Danny Nguyen and has published in prestigious journals such as Journal of Clinical Oncology, Biometrics and Annals of Oncology.

In The Last Decade

Veronica Bunn

25 papers receiving 412 citations

Hit Papers

Treatment Outcomes and Safety of Mobocertinib in Platinum... 2021 2026 2022 2024 2021 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer
    2021 196 citations Caicun Zhou, Suresh S. Ramalingam et al. JAMA Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Veronica Bunn United States 9 256 215 121 98 82 26 422
Elisa Rizzo Italy 6 132 0.5× 190 0.9× 97 0.8× 47 0.5× 76 0.9× 7 343
Ray Lin United States 11 272 1.1× 280 1.3× 73 0.6× 123 1.3× 50 0.6× 27 613
Mirat Shah United States 9 155 0.6× 263 1.2× 136 1.1× 107 1.1× 137 1.7× 18 549
Gautier Paux France 9 110 0.4× 115 0.5× 64 0.5× 41 0.4× 50 0.6× 26 394
Heiko Götte Germany 8 483 1.9× 369 1.7× 104 0.9× 92 0.9× 51 0.6× 23 761
Melissa D. Curtis United States 6 217 0.8× 258 1.2× 49 0.4× 45 0.5× 78 1.0× 8 427
Emmanuel Zuber Switzerland 8 209 0.8× 148 0.7× 188 1.6× 52 0.5× 42 0.5× 15 458
Melisa Tucker United States 9 301 1.2× 357 1.7× 70 0.6× 52 0.5× 123 1.5× 13 566
Jonathon Vallejo United States 12 152 0.6× 309 1.4× 68 0.6× 86 0.9× 72 0.9× 31 530
Gwynn Ison United States 9 90 0.4× 216 1.0× 71 0.6× 65 0.7× 102 1.2× 16 439

Countries citing papers authored by Veronica Bunn

Since Specialization
Citations

This map shows the geographic impact of Veronica Bunn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Veronica Bunn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Veronica Bunn more than expected).

Fields of papers citing papers by Veronica Bunn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Veronica Bunn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Veronica Bunn. The network helps show where Veronica Bunn may publish in the future.

Co-authorship network of co-authors of Veronica Bunn

This figure shows the co-authorship network connecting the top 25 collaborators of Veronica Bunn. A scholar is included among the top collaborators of Veronica Bunn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Veronica Bunn. Veronica Bunn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yang, Yunlong, et al.. (2024). Covariate adjusted meta-analytic predictive (CA-MAP) prior for historical borrowing using patient-level data. Journal of Biopharmaceutical Statistics. 34(6). 944–952.
2.
Le, Xiuning, Jacqulyne Robichaux, Monique B. Nilsson, et al.. (2023). 1377P Differential impact of EGFR exon 20 insertion location on tyrosine kinase inhibitor sensitivity. Annals of Oncology. 34. S790–S790. 2 indexed citations
3.
Wu, Liwen, et al.. (2023). Evolution of Phase II Oncology Trial Design: from Single Arm to Master Protocol. Therapeutic Innovation & Regulatory Science. 57(4). 823–838. 6 indexed citations
4.
Zhou, Chenhao, Jiafeng Fang, Jian-Lan Zhou, et al.. (2023). 586P Clinical validation of a multiplex polymerase chain reaction (mPCR) assay to identify patients (pts) with NSCLC suitable for mobocertinib treatment. Annals of Oncology. 34. S1699–S1699. 1 indexed citations
5.
Jänne, Pasi A., Suresh S. Ramalingam, James Chih‐Hsin Yang, et al.. (2022). Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic non–small cell lung cancer (mNSCLC): Treatment (tx) beyond progressive disease (PD) in platinum-pretreated patients (pts) with and without intracranial PD.. Journal of Clinical Oncology. 40(16_suppl). 9099–9099. 6 indexed citations
6.
Vincent, Sylvie, Zhenqiang Su, Veronica Bunn, et al.. (2022). Molecular analysis of circulating tumor DNA (ctDNA) in patients (pts) with EGFR exon 20 insertion-positive (ex20ins+) advanced NSCLC treated with mobocertinib.. Journal of Clinical Oncology. 40(16_suppl). 9108–9108. 2 indexed citations
7.
Bunn, Veronica, et al.. (2022). Bayesian Additive Regression Trees (BART) with covariate adjusted borrowing in subgroup analyses. Journal of Biopharmaceutical Statistics. 32(4). 613–626. 6 indexed citations
8.
Bunn, Veronica, et al.. (2021). Propensity‐score‐based meta‐analytic predictive prior for incorporating real‐world and historical data. Statistics in Medicine. 40(22). 4794–4808. 31 indexed citations
9.
10.
Christopoulos, Petros, S-H.I. Ou, Jianchang Lin, et al.. (2021). 1224P Systematic review and meta-analysis of immunotherapy effectiveness for pretreated patients with non-small cell lung cancer harboring EGFR exon 20 insertions. Annals of Oncology. 32. S972–S972. 2 indexed citations
11.
Zhou, C., Suresh S. Ramalingam, Jian Fang, et al.. (2021). OA04.03 Mobocertinib in NSCLC With EGFR Exon 20 Insertions: Results From EXCLAIM and Pooled Platinum-Pretreated Patient Populations. Journal of Thoracic Oncology. 16(3). S108–S108. 21 indexed citations
12.
Jänne, Pasi A., Suresh S. Ramalingam, James Chih‐Hsin Yang, et al.. (2021). FP09.01 Mobocertinib in Platinum-Pretreated EGFR Exon 20 Insertion+ Metastatic NSCLC Patients With/Without Prior Anti-PD(L)-1 Therapy. Journal of Thoracic Oncology. 16(10). S960–S960. 2 indexed citations
13.
Zhou, Caicun, Suresh S. Ramalingam, Tae Min Kim, et al.. (2021). Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer. JAMA Oncology. 7(12). e214761–e214761. 196 indexed citations breakdown →
14.
Brownstein, Naomi C., Veronica Bunn, Luis M. Castro, & Debajyoti Sinha. (2020). Bayesian analysis of survival data with missing censoring indicators. Biometrics. 77(1). 305–315. 2 indexed citations
15.
Bunn, Veronica, et al.. (2020). Flexible Bayesian subgroup analysis in early and confirmatory trials. Contemporary Clinical Trials. 98. 106149–106149. 5 indexed citations
16.
Riely, Greg J., Joel W. Neal, D. Ross Camidge, et al.. (2020). 1261MO Updated results from a phase I/II study of mobocertinib (TAK-788) in NSCLC with EGFR exon 20 insertions (exon20ins). Annals of Oncology. 31. S815–S816. 15 indexed citations
17.
Kim, Edward S., Sai‐Hong Ignatius Ou, Fabrice Barlési, et al.. (2019). Phase 2 study of brigatinib in patients (pts) with anaplastic lymphoma kinase (ALK)−positive, advanced non–small cell lung cancer (NSCLC) that progressed on alectinib or ceritinib.. Journal of Clinical Oncology. 37(15_suppl). TPS9115–TPS9115. 4 indexed citations
18.
Lin, Jianchang, Veronica Bunn, & Rachael Liu. (2019). Practical Considerations for Subgroups Quantification, Selection and Adaptive Enrichment in Confirmatory Trials. Statistics in Biopharmaceutical Research. 11(4). 407–418. 8 indexed citations
19.
20.
Lin, Jianchang & Veronica Bunn. (2017). Comparison of multi-arm multi-stage design and adaptive randomization in platform clinical trials. Contemporary Clinical Trials. 54. 48–59. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elisa Rizzo Breakdown of academic impact, for papers by Ray Lin Breakdown of academic impact, for papers by Mirat Shah Breakdown of academic impact, for papers by Gautier Paux Breakdown of academic impact, for papers by Heiko Götte Breakdown of academic impact, for papers by Melissa D. Curtis Breakdown of academic impact, for papers by Emmanuel Zuber Breakdown of academic impact, for papers by Melisa Tucker Breakdown of academic impact, for papers by Jonathon Vallejo Breakdown of academic impact, for papers by Gwynn Ison
Rankless by CCL
2026